Gilbert Cisneros Buys Shares of Arcutis Biotherapeutics, Inc. $ARQT
Key Points
- Gilbert Cisneros bought Arcutis Biotherapeutics, Inc. ($ARQT) stock ($1,001 - $15,000).
- The trade was disclosed by a member of the House.
- $ARQT last traded around $24.59.
Gilbert Cisneros vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Gilbert Cisneros, a member of the House, bought $1,001 - $15,000 of Arcutis Biotherapeutics, Inc. ($ARQT) stock on 2026-05-29, according to a periodic transaction report filed under the STOCK Act. Disclosures are filed after the trade and reflect a dollar range, not an exact amount.
Arcutis Biotherapeutics, Inc. ($ARQT) Stock
Arcutis Biotherapeutics, Inc. Earnings
Analysts Set New Price Targets
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.